MAFFONGELLI, GAETANO
 Distribuzione geografica
Continente #
NA - Nord America 3.966
EU - Europa 352
AS - Asia 350
Continente sconosciuto - Info sul continente non disponibili 2
OC - Oceania 2
SA - Sud America 1
Totale 4.673
Nazione #
US - Stati Uniti d'America 3.962
SG - Singapore 147
KR - Corea 132
DE - Germania 63
CN - Cina 59
SE - Svezia 59
IE - Irlanda 47
IT - Italia 47
UA - Ucraina 44
RU - Federazione Russa 31
GB - Regno Unito 23
FR - Francia 16
FI - Finlandia 8
CA - Canada 4
HK - Hong Kong 4
PL - Polonia 4
BE - Belgio 3
KG - Kirghizistan 3
AU - Australia 2
CZ - Repubblica Ceca 2
ES - Italia 2
NL - Olanda 2
VN - Vietnam 2
A2 - ???statistics.table.value.countryCode.A2??? 1
BA - Bosnia-Erzegovina 1
BD - Bangladesh 1
CL - Cile 1
EU - Europa 1
JP - Giappone 1
SA - Arabia Saudita 1
Totale 4.673
Città #
Wilmington 1.350
Houston 890
Woodbridge 692
Fairfield 185
Chandler 152
Singapore 131
Ashburn 81
Seattle 78
Ann Arbor 71
Cambridge 69
Dublin 40
New York 37
Medford 35
Dearborn 30
Santa Clara 29
Beijing 27
Rome 23
Jacksonville 20
Menlo Park 20
Lawrence 17
San Diego 8
Zhengzhou 7
Hefei 6
London 6
Munich 6
Milan 5
Moscow 5
Palo Alto 5
Hong Kong 4
Kraków 4
Roebling 4
Toronto 4
Brussels 3
Città Sant'Angelo 3
Seoul 3
Shanghai 3
Shenyang 3
University Park 3
Amsterdam 2
Chieti 2
Dong Ket 2
Falls Church 2
Guangzhou 2
Helsinki 2
Kunming 2
Nanjing 2
Norwalk 2
Olomouc 2
Pomezia 2
Redwood City 2
Saint Petersburg 2
San Jose 2
A Coruña 1
Baotou 1
Boardman 1
Bolton 1
Büdelsdorf 1
Changsha 1
Clearwater 1
Clifton 1
Fuzhou 1
Genoa 1
Hounslow 1
Kilburn 1
Lappeenranta 1
Los Angeles 1
Mountain View 1
Mülheim 1
Nanning 1
Phoenix 1
Pittsboro 1
Redmond 1
Riyadh 1
Rostock 1
Saint Paul 1
San Francisco 1
Sarajevo 1
Sydney 1
Tokyo 1
Wandsworth 1
Xian 1
Totale 4.116
Nome #
Comparative evaluation of subtyping tools for the surveillance of newly emerging HIV-1 strains 412
Hepatitis B reactivation characterized by HBsAg negativity and anti-HbsAg antibodies persistence in haematopoietic stem cell transplanted patient after lamivudine withdrawal 397
Performance of genotypic tropism testing on proviral DNA in clinical practice: results from the DIVA Study Group 374
Genotypic testing on HIV-1 DNA as a tool to assess HIV-1 co-receptor usage in clinical practice: results from the DIVA study group 372
Structural equation modelling of viral tropism reveals its impact on achieving viral suppression within 6 months in treatment-naive HIV-1-infected patients after combination antiretroviral therapy 345
High rates of chronic HBV genotype E infection in a group of migrants in Italy from West Africa: Virological characteristics associated with poor immune clearance 327
Dynamics and phylogenetic relationships of HIV-1 transmitted drug resistance according to subtype in Italy over the years 2000-14 298
Infectious disease ward admission positively influences P. jiroveci pneumonia (PjP) outcome: A retrospective analysis of 116 HIV-positive and HIV-negative immunocompromised patients 280
Role of pretreatment variables on plasma HIV RNA value at the sixth month of antiretroviral therapy including all first line drugs in HIV naïve patients: A path analysis approach 262
Quantification of HIV-DNA and residual viremia in patients starting ART by droplet digital PCR: Their dynamic decay and correlations with immunological parameters and virological success 259
HBcAb seropositivity is correlated with poor HIV viremia control in an Italian cohort of HIV/HBV-coinfected patients on first-line therapy 240
Abnormal elevation of international normalized ratio in a patient during the coadministration of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide and warfarin: a case report 233
Prevalence of predicted resistance to doravirine in HIV-1-positive patients after exposure to non-nucleoside reverse transcriptase inhibitors 210
Cerebrospinal fluid HIV-1 escape according to different thresholds and underlying comorbidities: is it time to assess the definitions? 209
Remission of an HHV8-related extracavitary primary effusion lymphoma in an HIV-positive patient during antiretroviral treatment containing dolutegravir 181
Tuberculosis-related hospitalizations in a low-incidence country: A retrospective analysis in two Italian infectious diseases wards 175
Procalcitonin is a reliable marker of severe systemic infection in neutropenic haematological patients with mucositis 129
Sarilumab plus standard of care vs standard of care for the treatment of severe COVID-19: a phase 3, randomized, open-labeled, multi-center study (ESCAPE study) 29
Totale 4.732
Categoria #
all - tutte 10.964
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 10.964


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.075 0 0 0 0 135 143 166 144 149 119 114 105
2020/2021876 97 95 108 104 92 117 94 95 14 28 17 15
2021/2022227 8 16 12 25 16 10 8 7 39 23 15 48
2022/2023326 24 39 39 44 32 52 18 24 38 2 9 5
2023/202490 11 1 3 9 7 23 3 4 6 1 0 22
2024/2025251 12 138 58 25 18 0 0 0 0 0 0 0
Totale 4.732